Current Duke Appointments & Affiliations
Associate Professor of Medicine
·
2024 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Member of the Duke Cancer Institute
·
2016 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Scholarly Works
Mastocytosis: Part I: Pathogenesis, clinical presentation, and classification.
Journal article J Am Acad Dermatol · November 2026 Mast cells are tissue-resident immune cells which secrete numerous and varied immune mediators in response to a myriad of activation pathways and play an important physiological function in immunity, homeostasis, tissue repair, and nervous system regulatio ... Full text Link to item CiteMastocytosis: Part II: Diagnosis and management of mastocytosis through a multidisciplinary lens.
Journal article J Am Acad Dermatol · November 2026 Mastocytosis is a heterogeneous disorder marked by mast cell accumulation in various organs, presenting differently in children and adults. Red or brown maculopapular lesions on the skin should raise suspicion for mastocytosis. In children, presentations i ... Full text Link to item CiteVERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy.
Journal article J Clin Oncol · October 13, 2026 PURPOSE: Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by erythrocytosis. Rusfertide is a subcutaneous, injectable, hepcidin mimetic peptide that suppresses erythrocytosis. The phase III VERIFY trial evaluated the efficacy and safet ... Full text Link to item CiteRecent Grants
A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Clinical TrialPrincipal Investigator · Awarded by Incyte Corporation · 2026 - 2031A Phase 2/3, randomized, open-label, active-comparator-controlled,parallel-group, multicenter study to evaluate the safety and efficacy of bomedemstat (MK-3543) versus best available therapy in participants with polycythemia vera who have an inadequa
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme LLC · 2026 - 2031A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Clinical Study to Assess Efficacy and Safety of Ropeginterferon alfa-2b (P1101) in Adult Patients with Pre-fibrotic/Early Primary Myelofibrosis or Overt Primary Myelofibrosis at Low
Clinical TrialPrincipal Investigator · Awarded by PharmaEssentia Corporation · 2025 - 2030View All Grants
Education
University of North Dakota, School of Medicine and Health Sciences ยท
2008
M.D.